You are here: Industry Insights > Lynparza

News List

EC approves AstraZeneca and Merck’s Lynparza for two cancer types pharmaceutical-technology
November 06, 2020
AstraZeneca and Merck’s (MSD) Lynparza (olaparib) has secured approval from the European Commission for prostate cancer and ovarian cancer treatments in the European Union (EU).
GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval pharmatimes
September 23, 2020
GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
Lynparza scores long-term benefit data in BRCA-mutated ovarian cancer pharmatimes
September 22, 2020
AstraZeneca and MSD’s (Merck) PARP inhibitor Lynparza has demonstrated long-term progression-free survival (PFS) benefit in BRCA-mutated advanced ovarian cancer.
EU nod for Lynparza in pancreatic cancer pharmatimes
July 09, 2020
AstraZeneca and MSD's Lynparza (olaparib) has been approved in the EU for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
Lynparza Recommended for Approval in EU by CHMP for BRCA-Mutated Metastatic Pancreatic Cancer americanpharmaceuticalreview
June 10, 2020
AstraZeneca and Merck announced Lynparza (olaparib) has been recommended for marketing authorization in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
Lynparza backed by CHMP for BRCA-mutated pancreatic cancer pharmatimes
June 02, 2020
AstraZeneca and MSD's Lynparza (olaparib) has been recommended for marketing authorisation in the EU for the first-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
FDA approves Lynparza (olaparib) for HRR mutated prostate cancer europeanpharmaceuticalreview
May 26, 2020
Lynparza’s approval was based on results from a Phase III clinical trial in which it improved overall survival and progression-free survival in patients with certain prostate cancers.
AstraZeneca-Merck’s Lynparza gets US FDA nod for prostate cancer treatment expresspharma
May 21, 2020
The drug approval by the US regulator is for treating patients with a form of prostate cancer that could not be held back by standard hormone therapy.
Lynparza, Bevacizumab Combination Approved for HRD-Positive Advanced Ovarian Cancer in the US americanpharmaceuticalreview
May 15, 2020
AstraZeneca and Merck announced that Lynparza (olaparib) in combination with bevacizumab has been approved in the US for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
US nod for Lynparza in HRD-positive advanced ovarian cancer pharmatimes
May 12, 2020
AstraZeneca and MSD's Lynparza (olaparib) has been cleared in the US for use as a first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer.

Previous page 1 2 3 4 5 6 7 Next page